Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAK-preserved vs Preservative-free Latanoprost on Goblet Cells
NCT04957329Phase 4Recruiting
- Sponsor
- Rigshospitalet
- Start
- Sep 2021
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of latanoprost in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Rigshospitalet. Primary endpoint: Goblet cell density at 3 months. Started Sep 2021; status: recruiting.
02
Drugs
latanoprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT04957329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04957329.